After a stroke is diagnosed, eligible individuals receive a single infusion of the assigned treatment shortly after the event. They remain in the hospital for a few days for close monitoring of any side effects and for basic health checks. Follow‑up visits are scheduled over the next three months to track recovery, including assessments of neurological function and overall health. The study collects information on any serious bleeding events, other adverse reactions, and measures of disability and functional outcome during this period.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The purpose of the trial is to see if the additional antibiotic reduces the number of secondary infection episodes, including further episodes of sepsis, within 28 days. After enrollment, patients will continue their standard antibiotic treatment while receiving the study medication or placebo for up to seven days, followed by routine medical care and follow‑up visits to monitor health outcomes for the remainder of the month.

In the study, treatment is given over a long period of time, and people are followed while they receive one of the study medicines. The study looks at how often a blood clot in a vein happens after treatment starts. The medicines being studied are baricitinib, adalimumab, and etanercept.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

The purpose of the study is to find out whether the new medicine can improve breathing and reduce serious flare‑ups compared with the placebo. People who join will be randomly assigned to one of the two groups, and neither the participants nor the study staff will know which treatment each person receives (double‑blind). Over several months, participants will come to the clinic for routine visits where their lung function, symptoms and overall health will be checked.

During the study, participants will receive the injections at set intervals and will have simple breathing tests, such as measuring forced expiratory volume in one second (FEV1), which shows how much air can be exhaled quickly. They will also answer short questionnaires about how they feel, and will have basic safety checks like blood tests and a quick heart rhythm check (ECG). All of this information helps researchers see if the medicine works and is safe.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

The purpose of the study is to evaluate the effectiveness and safety of Bepirovirsen in achieving a functional cure for individuals with chronic hepatitis B who are already being treated with nucleos(t)ide analogues, a type of medication that helps control the virus. The study will last for 24 weeks, during which participants will receive Bepirovirsen with initial higher doses to help achieve the desired treatment effect. The goal is to see if Bepirovirsen can help reduce the virus to very low levels or eliminate it altogether, allowing participants to stop their current hepatitis B treatment.

Throughout the study, participants will be closely monitored to ensure their safety and to assess how well the treatment is working. The study aims to provide valuable information on whether Bepirovirsen can be an effective treatment option for people with chronic hepatitis B, potentially leading to a new way to manage this condition.

The purpose of this study is to find out if treatment with linvoseltamab alone or linvoseltamab combined with carfilzomib works better than standard treatments for multiple myeloma that has returned or stopped responding to previous therapy. The study will measure how many patients have no signs of cancer cells remaining in their body after twelve months of treatment and how long patients live without their cancer getting worse. The study will also look at how safe these treatments are and what side effects patients may experience.

The study has two parts. In the first part, a small number of patients will receive linvoseltamab or linvoseltamab with carfilzomib to check that the dosing schedule is safe. In the second part, a larger group of patients will be randomly assigned to receive either linvoseltamab alone, linvoseltamab with carfilzomib, or standard treatment combinations. Patients will receive their assigned treatment in cycles lasting twenty-eight days. During the study, patients will have regular check-ups, blood tests, and other examinations to see how well the treatment is working and to monitor for any side effects. The study will also ask patients questions about their quality of life and how they are feeling.

Patients in the study will be divided into different groups. Some groups will receive combinations of the study medications along with their standard care, while another group will receive only standard care. The medications will be given in different forms, including injections under the skin, injections into a vein, and liquids taken by mouth. Treatment will start within 36 hours after stroke symptoms begin and will continue for a certain period. During the study, patients will have regular check-ups and tests to see how they are doing.

The study will use brain imaging tests like CT scans and MRI to look at the brain and check for any bleeding or changes in the damaged area. Doctors will also measure how well patients can perform daily activities and check their stroke symptoms using special scoring systems. Blood tests will be done to measure medication levels and other substances in the blood. The study will also check for side effects, including whether patients develop depression, and will monitor overall safety throughout the treatment period.

The purpose of the study is to see if empasiprubart can help improve the ability to perform daily activities compared to placebo. The study will also look at how safe the medication is and how well it is tolerated by people with this nerve condition. Researchers want to understand if this treatment can help reduce disability and improve quality of life for people living with this condition.

The study is divided into two parts and will last up to about two years for each person who takes part. During the study, empasiprubart will be given through a needle into a vein, which is called an infusion. People taking part will have regular visits where doctors will check their muscle strength, ability to perform daily tasks, grip strength, and overall well-being. The study will also measure various safety aspects including blood tests, heart function tests, and any side effects that may occur. Throughout the study, researchers will collect blood samples to measure the levels of the medication in the body and to see how the immune system responds to the treatment.

The purpose of the study is to compare the effectiveness and safety of the two treatments in reducing the need for red blood cell transfusions. Participants are randomly assigned to receive either elritercept or epoetin alfa and will be treated for up to 24 weeks. During this time, they will have regular clinic visits where blood samples are taken to check hemoglobin levels, which indicate how well the blood is carrying oxygen, and doctors will record whether transfusions are still needed.

The study involves a series of visits scheduled roughly every few weeks. At each visit, a healthcare professional will administer the injection, perform a quick blood test, and ask about any side effects. The overall goal is to see if participants can stay without transfusions for a sustained period while their hemoglobin improves.

The purpose of the study is to evaluate how many participants experience a measurable reduction in their cancer using these combination therapies. Participants will receive the assigned medicines in cycles, attend regular clinic visits for blood checks, and undergo eye examinations because the investigational drug can affect the cornea, the clear front part of the eye. Terms such as “response rate” refer to the percentage of patients whose disease shrinks or disappears, while “adverse event” means any side effect that may occur, and “dose modification” means adjusting the amount of medicine if needed. The study will continue for several months, during which safety and effectiveness are closely monitored.

One group will receive sotorasib combined with a platinum doublet, which refers to a combination of two drugs like carboplatin and pemetrexed. The other group will receive pembrolizumab along with the same platinum doublet. Other medications, such as folic acid, hydroxocobalamin, dexamethasone, and antiemetics, may be used to support the treatment and manage side effects. During the study, the time until the cancer grows or worsens and the total length of time patients live are monitored.

During the study, participants will be assigned to one of two groups to receive either the new generic combination or the comparison medication. Both treatments are administered as eye drops. The process involves monitoring the pressure within the eye over a period of time to see how well each medicine works to lower these levels.

During the trial, participants will receive either tenecteplase or the standard of care via an intravenous bolus, which is a method of delivering medication directly into a vein in a single quick dose. The study will monitor how well patients recover and function over a period of time, specifically looking at their ability to perform daily activities 90 days after the event. The researchers will also observe for any potential side effects, such as symptomatic intracranial hemorrhage, which is a type of bleeding inside the brain that can occur following treatment.

The research involves two different approaches to treatment. In the first approach, ziftomenib is used alongside a nonintensive therapy consisting of venetoclax and azacitidine. In the second approach, ziftomenib is combined with an intensive therapy known as 7+3, which includes cytarabine and daunorubicin hydrochloride. Some participants may receive a placebo instead of ziftomenib to allow for a comparison between the different treatment methods.

During the study, participants will receive their assigned medications through different methods, such as oral pills or intravenous administration, which is the delivery of medicine directly into a vein. The study will monitor how long patients live and the time until the disease begins to grow again. This process helps determine if adding the new drug to standard treatments improves the long-term outcomes for people with these specific genetic forms of leukemia.

The purpose of this study is to show whether empasiprubart works better than human normal immunoglobulin in improving the ability to perform daily activities in adults with this nerve condition. During the study, participants will be randomly assigned to receive either empasiprubart or human normal immunoglobulin through a vein. The study uses a double-dummy design, which means that all participants will receive two infusions to ensure that neither the participants nor the doctors know which treatment is being given. The main assessment will happen at week 24, when doctors will measure changes in functional ability using a scoring system that evaluates arm and leg function.

Throughout the study, various measurements will be taken to assess how well participants can perform daily tasks, their muscle strength, their walking ability, and their overall quality of life. Grip strength will be measured regularly, and participants will complete questionnaires about their disability, fatigue, pain, and general health status. Blood samples will be taken to measure drug levels and to check for any immune responses to the treatment. Safety will be monitored by tracking any unwanted effects, changes in laboratory tests, heart rhythm recordings, and vital signs. The study will also look at how the treatments affect specific proteins in the blood that are involved in the immune response and nerve damage.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

The purpose of this study is to find out if the combination of xaluritamig plus abiraterone helps people with this type of prostate cancer live longer compared to the treatment chosen by their doctor. The study will also look at how long the cancer stays under control, whether the cancer shrinks or disappears, how long any improvement lasts, and how the treatments affect quality of life and symptoms such as pain. Additionally, the study will check for any unwanted effects of the treatments and measure how the body processes these medicines over time.

Participants in this study will be randomly assigned to receive either the combination of xaluritamig plus abiraterone or one of the treatments chosen by their doctor. During the study, participants will have regular check-ups where doctors will use imaging tests like computed tomography scans, magnetic resonance imaging scans, or bone scans to see how the cancer is responding to treatment. Blood tests will be done to check organ function and measure levels of prostate-specific antigen, which is a substance in the blood that can indicate how the cancer is responding. Participants will also be asked to complete questionnaires about their pain levels, side effects, and overall quality of life throughout the study. The study will continue until enough information is collected to determine which treatment approach works better.

People taking part in this study will already be receiving treatment for their condition with either steroid medications taken by mouth or immunoglobulin therapy given through a vein or under the skin. During the study, participants will be checked regularly to see if their symptoms worsen or stay stable. The study will look at different measures of how well people can perform daily activities and how strong their muscles are, including grip strength in the dominant hand and overall muscle strength.

The study will last for several years and will involve multiple visits where various assessments will be done. The main focus will be on measuring whether people remain free from worsening of their condition over a period of 24 weeks. Other measurements will include changes in the ability to perform daily tasks, hand grip strength, and overall muscle strength at the same time point.

The study will focus on people who have mild to moderate Alzheimer’s Disease, which is a brain condition that affects memory, thinking, and behavior. The medications will be tested to see if they can help improve cognitive function (thinking and memory skills) and overall daily functioning in people with this condition.

During the study, which will last 24 weeks, participants will take the study medications or placebo daily. Healthcare providers will monitor participants’ thinking abilities, daily functioning, and overall condition throughout the study period. They will also check for any side effects or safety concerns that may occur during treatment.

The treatment will involve taking PF-07248144 tablets by mouth along with fulvestrant injections into the muscle. Some patients will receive this combination, while others will receive different standard treatments such as everolimus or exemestane. The purpose is to determine if the combination of PF-07248144 and fulvestrant works better than currently available treatments in stopping the cancer from growing.

The study will last for up to 24 months. During this time, patients will have regular check-ups to monitor their health and see how well the treatment is working. Doctors will use special scans to measure if tumors are shrinking, staying the same size, or growing. They will also keep track of any side effects that patients may experience during the treatment.

The study involves patients taking either efavaleukin alfa or placebo while continuing their current medications such as 5-aminosalicylates, corticosteroids, budesonide, beclomethasone dipropionate, or other immune system medications like azathioprine, 6-mercaptopurine, or methotrexate. The main purpose is to evaluate if efavaleukin alfa can help patients achieve clinical remission after 12 weeks of treatment.

During the study, doctors will monitor how well the treatment works by examining the digestive tract and checking for improvements in symptoms. They will also keep track of any side effects that may occur. The study is designed as a double-blind study, which means neither the patients nor the doctors know who is receiving the actual medication or the placebo during the treatment period.

The study aims to understand the long-term safety and effectiveness of efavaleukin alfa in treating people who have moderate to severe Ulcerative Colitis. This research is a continuation of a previous study, allowing researchers to gather information about how well the medication works and how safe it is when used for an extended period.

During this long-term extension study, participants will continue receiving efavaleukin alfa treatment for up to two years. Throughout this time, doctors will monitor various aspects of the participants’ health, including how well their digestive system is healing and whether their symptoms are improving. They will also keep track of any side effects that may occur during the treatment period.

The study medication Tozorakimab will be given as an injection under the skin, alongside the regular COPD treatments that participants are already taking. Some participants will receive Tozorakimab while others will receive placebo, in addition to their standard COPD medications. Participants may also use salbutamol, a rescue inhaler medication that helps to quickly relieve breathing difficulties when needed.

The study will last for 52 weeks, during which participants will need to attend regular clinic visits for health assessments. Throughout the study, doctors will monitor how often participants experience COPD flare-ups, which are periods when their symptoms become notably worse than usual. These flare-ups can range from moderate to severe and may require additional medical treatment.

Multiple Myeloma is a type of blood cancer that affects plasma cells, which are special white blood cells that help fight infections. The study aims to determine which treatment combination is more effective at eliminating cancer cells to a level that cannot be detected by very sensitive testing methods.

The medications used in this study are given in different ways. Lenalidomide is taken by mouth in capsule form, while Daratumumab and Linvoseltamab are given through an infusion into a vein. Dexamethasone can be given either as tablets by mouth or as an injection. The treatment continues for several weeks, and patients will need regular visits to the hospital for monitoring and receiving their medications.

The purpose is to determine if BEM/RZR treatment, given once daily for either 8 or 12 weeks, works as well as SOF/VEL treatment, which is given once daily for 12 weeks. These medications work by directly targeting the virus that causes the infection.

During the study, participants will receive one of these treatments and will have their virus levels monitored through blood tests. The study will track how well the medications clear the virus from the body and whether the infection returns after treatment ends. The total duration of monitoring for each participant extends to 24 weeks to ensure long-term effectiveness of the treatment.

The purpose of this research is to determine if AZD0780 can reduce the risk of serious cardiovascular events such as heart attacks, strokes, and problems with blood flow to the legs in people with cardiovascular disease. The medication will be tested in addition to patients’ regular cholesterol-lowering treatments.

During the study, participants will receive either AZD0780 or a placebo for up to 54 months. The study team will monitor participants for any cardiovascular events, including heart-related death, heart attacks, strokes, severe leg circulation problems, and emergency procedures to restore blood flow. Throughout the study, participants will continue their usual heart medications, including their regular cholesterol-lowering treatments.

The purpose of this research is to determine how well ibuzatrelvir works when used alone or combined with remdesivir in treating COVID-19 symptoms and reducing the amount of virus in people with weakened immune systems. The study includes people who have received organ transplants, those with blood cancers, individuals who have received certain cancer treatments, or those taking medications that affect their immune system.

During the study, participants will receive the study medication for up to three days. They will be monitored for changes in their COVID-19 symptoms and the amount of virus in their body. The study will track whether participants need emergency care, hospital treatment, or experience other health problems related to COVID-19. The total study period is 38 days, during which participants will have regular check-ups to monitor their health and any side effects.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The treatment involves taking these medications in cycles. Some participants will receive bleximenib along with venetoclax and azacitidine, while others will receive venetoclax and azacitidine with a placebo. This is a double-blind study, which means neither the participants nor the researchers will know which treatment group a participant is in until the study is completed.

The study will monitor how participants respond to treatment by tracking various health indicators and will assess whether the addition of bleximenib improves complete remission (when there are no detectable cancer cells) and overall survival in patients with this type of leukemia.

The purpose of this study is to evaluate whether the combination of golcadomide and rituximab is more effective than other treatment options chosen by investigators for patients whose follicular lymphoma has not responded well to previous therapies. During the study, participants will receive either the combination treatment or another treatment selected by their doctor.

The study will track various outcomes including how long participants live without their disease getting worse, overall survival time, how well the cancer responds to treatment, and how the treatment affects quality of life. Participants must be over 18 years of age and meet specific health criteria to join the study.